Merion

Merion EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Merion (EWLU) as of Nov 1, 2026 is 40.51 %. In the previous year, Year-over-Year EBITDA Growth was -100.31 % — a change of -140.38% (higher).

EBITDA Growth YoY

40.51 %

YoY

-140.38%

Last updated:

Year-over-Year EBITDA Growth of Merion is 2021 40.51 % . Year-over-Year EBITDA Growth of Merion was 2020 -100.31 % . It decreases by -140.38% higher compared to the previous year.

The Merion EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2015
-212.54 USD
Jan 1, 2016
79.62 USD
Jan 1, 2017
-10.97 USD
Jan 1, 2018
-231.90 USD
Jan 1, 2019
61.47 USD
Jan 1, 2020
-100.31 USD
Jan 1, 2021
40.51 USD
The Merion EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
40.51 %-140.38%
-100.31 %-263.20%
61.47 %-126.51%
-231.90 %+2,014.43%
-10.97 %-113.77%
79.62 %-137.46%
-212.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Merion Stock analysis

What does Merion do? Merion, Inc. generates revenue by selling its own line of seven nutritional supplements and seven skin-care products through its website dailynu.com. The company's nutritional supplements, including Dibeier Granules & Oral, Longevity, US-Liver Gold, Cell Power, OPC Spa, Heart Power, and O2 Cell Power, are formulated using a micro molecular nutrition process. Its skin-care products, such as anti-aging cream, facial cream, facial serum, body lotion, sun protection, facial toner, and facial cleanser, focus on restoring epidermal calcium. The firm also sells third-party health and nutrition products that are already available through other vendors. The company's primary customers are individuals seeking health and nutritional supplements and personal care products, purchasing directly through dailynu.com. Merion does not manufacture its own skin-care products but distributes third-party brands that are already sold by other vendors. The firm's revenue streams include direct sales of its proprietary supplement line and the third-party products it resells. Merion's business model relies on e-commerce sales via its website, with no physical retail presence. The company's product portfolio is divided into two main segments: its own micro molecular nutrition supplements and third-party health and nutrition products. The skin-care segment focuses on products that restore epidermal calcium, while the nutritional segment features seven proprietary supplements made using its unique formula. Merion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merion stock

Year-over-Year EBITDA Growth of Merion is 40.51 % in 2021.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Merion since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Merion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Merion

All Key Metrics — Merion